IFNG and neoplasm: We used the T cell inflamed immune signature, composed of active IFN-γ signaling, cytotoxic effector, and antigen presentation molecules, and T cell active cytokines that were previously sequentially validated to predict response to standard immunotherapy in HNSCC, as well as other tumor types (15).